VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody IHC staining of lung adenocarcinoma tissue Roche’s VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market The biomarker may provide a cost-effective and efficient means to initially identify elevated ROS1 protein expression in cancer ROS1-positive cancer... Read more
Basel, 16 May 2019 Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta offers more adults with chronic lymphocytic leukaemia... Read more
Basel, 16 May 2019 Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) fusions, including those in the central nervous... Read more
Basel, 14 May 2019 New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis... Read more
Basel, 14 May 2019 Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. Parties elect to refile Premerger Notification and Report Forms on or about 23 May 2019 to provide the government with additional... Read more
Basel, 10 May 2019 Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duration combination of Venclexta/Venclyxto... Read more
Basel, 08 May 2019 Roche to present new OCREVUS (ocrelizumab) data analyses showing significant reduction of disability progression in relapsing and primary progressive multiple sclerosis at the AAN Annual Meeting New analyses show the effect of OCREVUS on reducing the risk of disability progression is associated with exposure and lower B-cell levels Long-term data in... Read more
Basel, 07 May 2019 Roche presents data from the risdiplam pivotal FIREFISH and SUNFISH studies in spinal muscular atrophy at the 2019 AAN Annual Meeting In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond those expected in the natural history of the disease New... Read more
Basel, 06 May 2019 FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast... Read more
Basel, 29 April 2019 New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New analyses in relapsing and primary... Read more